Nature Cell Biology study finds new coronary atherosclerosis cell subtype and biomarker

A Nature Cell Biology study published in July 2026 identified a disease-driving endothelial cell subtype in human coronary atherosclerosis and validated osteoglycin, or OGN, as a potential blood-based biomarker. Cloud-Clone said its OGN ELISA kit supported the serum testing used in the translational study.

Why it matters: - Human coronary atherosclerosis is hard to study because graded human tissue is scarce and common animal models do not fully reflect human vascular disease. - A simple blood biomarker could help screen high-risk patients, track disease burden and reduce reliance on costly, radiation-based coronary CTA exams. - The study links cell-level disease mechanisms to a non-invasive marker, which strengthens the path from discovery research to clinical use.

What happened: - Researchers from Fuwai Hospital and the State Key Laboratory of Cardiovascular Disease published the study in Nature Cell Biology in July 2026. - The paper, titled "Single-cell transcriptomics uncovers endothelial progenitor-like remodelling driving human coronary atherosclerosis progression," used staged human coronary single-cell atlases to study disease progression. - Cloud-Clone said its OGN ELISA assay was used for high-throughput protein quantification across clinical serum cohorts.

The details: - The team collected 56 human coronary artery segments from 19 heart-transplant donors. - The samples were categorized as normal, early-stage atherosclerosis and advanced-stage atherosclerosis. - Single-cell sequencing captured 27,941 high-quality cells. - Researchers identified nine major cell classes and 37 vascular and immune cell sub-populations, including endothelial cells, vascular smooth-muscle cells, fibroblasts, macrophages, T cells, B cells and mast cells. - The study identified a previously unrecognized endothelial population, EC5 SLCO4A1+. - EC5 SLCO4A1+ cells expanded as lesions progressed and showed reduced barrier genes, higher migratory and angiogenic capacity, and weaker vascular barrier integrity. - Those traits appear to support lipid entry and immune-cell recruitment into the intima. - PRDM15 was identified as the master regulator of the EC5 state. - CUT&Tag sequencing showed PRDM15 directly binds genomic loci to activate SLCO4A1 and other EC5-signature genes. - In ApoE-/- mouse models, endothelial-specific Prdm15 overexpression enlarged aortic and coronary plaques, expanded necrotic cores, increased macrophage infiltration and reduced plaque stability. - Endothelial-specific Prdm15 deletion reduced atherosclerotic lesions, shrank plaque volume, thickened fibrous caps, improved plaque stability and lowered EC5-like pathogenic endothelial cells. - Cell-communication analysis found a pro-inflammatory loop between EC5 SLCO4A1+ cells and plaque macrophages. - EC5 cells secrete CXCL9, while pro-inflammatory macrophages express CCL3. - The study short-listed 25 secreted protein candidates with stage-dependent expression changes. - A clinical cohort of 148 patients receiving coronary CTA was used to test biomarker potential. - Serum OGN levels correlated positively with coronary artery calcification score, a readout for total coronary atherosclerotic burden. - The publication referenced the Cloud-Clone OGN (Osteoglycin) ELISA Kit, Cat. No. USEC688Hu. - Cloud-Clone said OGN can be measured in serum, plasma, cell-culture supernatants and tissue homogenates.

Between the lines: - The study suggests coronary plaque progression is driven not just by lipid buildup, but by endothelial reprogramming and immune signaling inside the vessel wall. - The EC5 SLCO4A1+ subtype and the PRDM15-SLCO4A1 axis point to a specific biological pathway that could be explored for future therapies. - OGN’s correlation with calcium burden does not yet make it a validated clinical test, but it does make the protein a plausible candidate for broader validation.

What's next: - Larger cohorts are needed to confirm whether OGN can predict coronary disease severity, major cardiovascular events and outcomes in patients with diabetes, hyperlipidaemia and chronic kidney disease. - Additional work may test whether blocking PRDM15 or disrupting the CXCL9-CCL3 inflammatory loop can stabilize plaques. - The publicly available human coronary single-cell dataset may be mined for more biomarker and drug-target candidates. - The study’s authors and Cloud-Clone frame the work as a platform for future translational cardiovascular research and biomarker development.

The bottom line: - The paper identifies a new pathogenic endothelial cell state in human coronary atherosclerosis and links it to both plaque progression and a circulating biomarker candidate.